Celcuity CELC
NASDAQ CELC
$95.70 -0.73 (-0.76%)
As of: Sep 4, 2026 · 3:59 PM EDT

Celcuity (CELC) Cash from Investing Activities (2016 - 2025)

Celcuity's (CELC) quarterly Cash from Investing Activities came in at $103.4 million in Q4 2025, up 175.32% YoY from $37.6 million in Q4 2024, and up 140.14% on a QoQ basis from -$257.6 million in Q3 2025.

Analysis

Celcuity (CELC) Cash from Investing Activities (2016 - 2025) Analysis & Trends

Celcuity (CELC) has 10 years of Cash from Investing Activities data on file, last reported at $103.4 million in Q4 2025.

  • Quarterly Cash from Investing Activities rose 175.32% year-over-year to $103.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$64.1 million (down 1.61% YoY) and the FY2025 annual result came in at -$64.1 million, down 1.61% from the prior year.
  • Cash from Investing Activities improved to $103.4 million in Q4 2025, from -$257.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $103.4 million in Q4 2025 to a low of -$257.6 million in Q3 2025.
  • A 5-year average of -$13.8 million and a median of -$10787.0 in 2021 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1448587.69% — and 2023, when it jumped 188046.29%.
  • Tracing CELC's Cash from Investing Activities over 5 years: stood at -$9939.0 in 2021, then sank by 1448587.69% to -$144.0 million in 2022, then surged by 71.37% to -$41.2 million in 2023, then jumped by 191.12% to $37.6 million in 2024, then jumped by 175.32% to $103.4 million in 2025.
  • The last three Cash from Investing Activities figures came in at $103.4 million (Q4 2025), -$257.6 million (Q3 2025), and $65.9 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Celcuity 5.25 Bn 5.25 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 103.41 Mn
Sep 30, 2025 -257.61 Mn
Jun 30, 2025 65.86 Mn
Mar 31, 2025 24.26 Mn
Dec 31, 2024 37.56 Mn
Sep 30, 2024 1.90 Mn
Jun 30, 2024 -106.07 Mn
Mar 31, 2024 3.54 Mn
Dec 31, 2023 -41.22 Mn
Sep 30, 2023 6.25 Mn
Jun 30, 2023 8.09 Mn
Mar 31, 2023 21.87 Mn
Dec 31, 2022 -143.99 Mn
Sep 30, 2022 -12,103.00
Jun 30, 2022 -22,986.00
Mar 31, 2022 -11,635.00
Dec 31, 2021 -9,939.00
Sep 30, 2021 -14,062.00
Jun 30, 2021 -26,972.00
Mar 31, 2021 -30,425.00